$68.51 0.00 (%) AbbVie Inc - NYSE

Jul. 1, 2015 | 04:00 PM

Partner Headlines

  1. Juno, Celgene Lead 5 Top Biotechs Nearing Buy Point

    IBD | Jul. 1, 2015 | 17:43PM EST
  2. Can Hepatitis B Be A Blockbuster Bug?

    IBD | Jul. 1, 2015 | 08:02AM EST
  3. Enanta is growing thanks to collaborations.

    GuruFocus | Jun. 29, 2015 | 17:16PM EST
  4. Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent

    Benzinga | Jun. 29, 2015 | 14:44PM EST
  5. Acquisitions May Fuel Gilead Sciences' Winning Ways

    IBD | Jun. 26, 2015 | 17:28PM EST
  6. Intrexon, Enanta Among Top Biotech New Issues

    IBD | Jun. 24, 2015 | 17:19PM EST
  7. US Stock Futures Slide Ahead Of GDP Data

    Benzinga | Jun. 24, 2015 | 07:13AM EST
  8. AbbVie Reports Phase 3B Results in Genotype 1b Chronic Hep C Patients with Compensated Liver Cirrhosis

    Benzinga | Jun. 24, 2015 | 06:01AM EST
  9. Where Can Mega-Drug Stock Gilead Sciences Go Now?

    IBD | Jun. 22, 2015 | 13:56PM EST
  10. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga | Jun. 22, 2015 | 09:29AM EST
  11. The Note Moving Pharma Giants Today

    Benzinga | Jun. 17, 2015 | 16:06PM EST
  12. New Report: Abbvie Is Jefferies' Top Global Pharma Stock

    Benzinga | Jun. 16, 2015 | 12:15PM EST
  13. AbbVie to Present Data from Studies of DUOPA Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders

    Benzinga | Jun. 12, 2015 | 09:00AM EST
  14. Why Drugmaker AbbVie Can Power Past Patent Expiration

    IBD | Jun. 11, 2015 | 13:13PM EST
  15. Skyworks, Nike Among Big Cap 20 Stocks Pulling Back

    IBD | Jun. 8, 2015 | 18:22PM EST
  16. This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says

    Benzinga | Jun. 8, 2015 | 14:03PM EST
  17. Jefferies Adds AbbVie To Franchise Pick List After Conducting HumiraCo Deep Dive

    Benzinga | Jun. 8, 2015 | 09:32AM EST
  18. Morgan Stanley: Time To Buy Galapagos

    Benzinga | Jun. 8, 2015 | 07:56AM EST
  19. Halozyme Stock Hits New High On AbbVie Collaboration

    IBD | Jun. 3, 2015 | 15:28PM EST
  20. UBS Reviews ASCO, Notes Weekend Data Points From 2 Companies

    Benzinga | Jun. 1, 2015 | 09:38AM EST
  21. Larry Robbins' New Buys During Q1 2015

    GuruFocus | May. 29, 2015 | 19:21PM EST
  22. Gilead Hangs Tough Despite Challenges In Hep C Market

    IBD | May. 29, 2015 | 18:53PM EST
  23. Top Biotech Stock Illumina Hunts For Breakout Gene

    IBD | May. 29, 2015 | 18:31PM EST
  24. Breakout Watch: AbbVie Testing New Buy Point

    IBD | May. 28, 2015 | 11:26AM EST
  25. Morgan Stanley Calls AbbVie 'Unpredictable' With 'Upside'

    Benzinga | May. 28, 2015 | 08:52AM EST
  26. Stock Indexes Rebound Strongly; Microsoft, Intel Lead Blue Chips

    IBD | May. 27, 2015 | 16:17PM EST
  27. 5 Drugs That Could Be Summer Blockbusters

    IBD | May. 27, 2015 | 15:54PM EST
  28. Avago Technologies Breaks Out As Stock Market Rebound Holds

    IBD | May. 27, 2015 | 15:15PM EST
  29. NWQ's First-Quarter Buys and Adds Affect Portfolio

    GuruFocus | May. 26, 2015 | 17:36PM EST
  30. Ambarella Leads 3 Top Stocks Bucking The Sell-Off

    IBD | May. 26, 2015 | 15:20PM EST
  31. This Medical Stock Refuses To Fall With Major Stock Indexes

    IBD | May. 26, 2015 | 13:21PM EST
  32. Stocks Slump On Strong Dollar, Economic Data; AbbVie Rises

    IBD | May. 26, 2015 | 11:57AM EST
  33. AbbVie Makes SEC Filings Relating To Its Previously Announced Agreement and Plan of Reorganization with Pharmacyclics, Inc.

    Benzinga | May. 26, 2015 | 11:47AM EST
  34. 5 Drugs That Could Be Summer Blockbusters

    IBD | May. 26, 2015 | 08:02AM EST
  35. AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics

    Benzinga | May. 22, 2015 | 08:03AM EST
  36. Benzinga's M&A Chatter for Thursday May 21, 2015

    Benzinga | May. 21, 2015 | 19:08PM EST
  37. Scott Black's Most Heavily Weighted Trades In Q1 2015

    GuruFocus | May. 21, 2015 | 18:58PM EST
  38. What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?

    Benzinga | May. 21, 2015 | 08:27AM EST
  39. Glenview Repeats AbbVie Bull Stance, Shuts Fund To Newbies

    Benzinga | May. 20, 2015 | 15:34PM EST
  40. Move Over Chip Stocks: Here Are 5 Top Biotechs

    IBD | May. 20, 2015 | 09:34AM EST
  41. Move Aside, Chip Stocks, Biotechs Are Leaders Too

    IBD | May. 20, 2015 | 08:02AM EST
  42. Achillion, J&J To Jointly Develop Hepatitis C Drugs

    IBD | May. 19, 2015 | 17:07PM EST
  43. Will The Bulls In Options Continue To Be Disappointed This Week?

    Benzinga | May. 18, 2015 | 14:17PM EST
  44. U.S. Loves Europe As Pharma, Energy Boost M&A

    IBD | May. 14, 2015 | 17:45PM EST
  45. IPO Outlook: Galapagos Offers New Hope For CF And RA Sufferers

    Benzinga | May. 12, 2015 | 13:45PM EST
  46. Regeneron, Nike Top Big Cap 20 Stocks Near Buy Points

    IBD | May. 11, 2015 | 19:16PM EST
  47. 9 Hot (Or Not) IPOs Scheduled To Debut This Week

    Benzinga | May. 11, 2015 | 08:30AM EST
  48. AbbVie Floats Mega-Bond Deal For Acquisition Funding

    GuruFocus | May. 8, 2015 | 13:38PM EST
  49. Pharmacyclics Posts A Mixed First Quarter Ahead Of Being Acquired By AbbVie

    GuruFocus | May. 7, 2015 | 13:16PM EST
  50. Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers

    Benzinga | May. 5, 2015 | 08:51AM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!